Ann: PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration, page-13

Hi M,

I still dont think that paper answers the toxicity question, some valid questions to ask of Geoffrey Kempler in email or at the next AGM:

Did the toxicity tests go high enough in dosage to satisfy FDA requirement?

Does all the pre clinical work in animals for PBT434 satisfy FDAs requirement in animal drug tolerance which held up PBT2 at the end of phase two?

Will the FDA ask to keep increasing the dosage until toxicity is reached further down the track , then require the Prana to put a plan together to negate side effects observed from toxicity in those animals?

It might have all been done and cleared but we just dont know from that paper...